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Abstract
By virtue of their accumulated genetic alterations, tumor cells may acquire vulnerabilities that create
opportunities for therapeutic intervention. We have devised a massively parallel strategy for
screening short hairpin RNA (shRNA) collections for stable loss-of-function phenotypes. We
assayed from 6000 to 20,000 shRNAs simultaneously to identify genes important for the proliferation
and survival of five cell lines derived from human mammary tissue. Lethal shRNAs common to these
cell lines targeted many known cell-cycle regulatory networks. Cell line–specific sensitivities to
suppression of protein complexes and biological pathways also emerged, and these could be validated
by RNA interference (RNAi) and pharmacologically. These studies establish a practical platform for
genome-scale screening of complex phenotypes in mammalian cells and demonstrate that RNAi can
be used to expose genotype-specific sensitivities.
The observation of genetic interactions is key to the definition of cellular networks. RNAi has
enabled genetic approaches in both cultured mammalian cells (1–5) and intact animals (6–9).
Large-scale screens of small interfering RNA (siRNA) (10–12) and shRNA collections (5,
13–16) have generally adopted a one-by-one approach, interrogating phenotypes in a well-
based format. This requires both considerable infrastructure and a substantial investment for
each cell line to be screened. Alternatively, shRNA collections can be screened by assaying
enrichment from pools, but this limits the range of phenotypes that can be addressed. Our focus
was identifying essential genes or synthetically lethal genetic interactions through shRNAs
that were selectively depleted from populations. This type of screen holds promise for the
discovery of novel targets for cancer therapy and genetically validated combination therapies.
Previously, one such screen was reported; however, this tested only ~500 shRNAs in a single
pool (17). We therefore sought methods that allow multiplex analysis of phenotypic outputs
on a genomic scale.
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Pooled libraries drew from our previous collections wherein shRNAs are carried in a backbone
derived from miR-30 (18). Combining RNA polymerase II promoters with miR-30–based
shRNAs permits efficient suppression even with a single-copy integrant (19,20). Therefore,
pooled shRNAs were transferred from pSM2 (18) to pLMP (19), wherein shRNA expression
is driven from the murine stem cell virus long-terminal repeat promoter. Three different pools,
containing ~6000, ~10,000, and ~20,000 shRNAs, were constructed to test screening at varying
scales and levels of population complexity. Target cell populations were infected such that
each cell contained, on average, a single integrated virus, and each individual shRNA occupied
~1000 cells. Three parallel infections generated biological replicate samples. Because our goal
was to identify essential genes, genomic DNA was prepared from each replicate at three time
points during a simple outgrowth assay (Fig. 1A).
Each shRNA cassette contains two unique identifiers: the shRNA itself and a random 60-
nucleotide barcode. Barcode sequences were determined for the human shRNA library, and
custom, multiplex format microarrays were prepared that contained both barcode and half-
hairpin (HH) probes (21) (Fig. 1B). Proviral DNA fragments encompassing both shRNAs and
barcodes were amplified from genomic DNA pools and hybridized to arrays in competition
with a common reference.
We established a rigorous data analysis pipeline (22) for analyzing pooled shRNA screens.
Correlations between biological replicates were high but diminished at later time points,
whereas correlations between the reference channels remained unchanged (table S1). Overall,
a gene was scored as a candidate if either its barcode or shRNA probe showed greater than 2-
fold change with a false discovery rate (FDR) <10%.
We began with a pooled analysis of 6000 (6K) shRNAs in MCF-10A and MDA-MB-435.
Although enriched gene sets varied considerably, similar numbers and largely overlapping
gene sets showed depletion in both cell lines (tables S2 and S3). Among negatively selected
shRNAs were many targeting regulators of the cell division cycle (23, 24) (table S3). These
included cyclins, cell division cycle (CDC) proteins, E2F family members, minichromosome
maintenance deficient genes, proliferating cell nuclear antigen, and RNA polymerase II–
associated genes. Additionally, the proteasome (15 of 25 subunits; P = 5.61 × 10−5) and
anaphase-promoting complex/cyclosome (APC/C) (6 of 11 subunits; P = 0.0139) scored as
being essential in both cell lines (table S3).
To validate candidates, we constructed a regulated shRNA vector, which linked shRNA and
green fluorescent protein expression (fig. S1A). Inducible shRNAs against two APC/C
subunits, ANAPC2 and 4, inhibited the growth of MCF-10A in a manner that correlated with
mRNA knockdown (fig. S1A and Fig. 2A). Similarly, MDAMB- 435 was sensitive to
ANAPC2 depletion (Fig. 2C). Nineteen additional MCF-10A lines were constructed with
inducible shRNAs targeting 11 different candidates (Fig. 2B). Of these, 16 lines exhibited
shRNA-dependent growth inhibition (30% to 95%), which correlated with mRNA knockdown
in 14 cases. The exceptions were CDC-5L and DKC-1, where growth suppression could be
due to off-target effects (Fig. 2B).
Among additional candidates were MAD2 and BUBR1, mitotic checkpoint proteins required
for regulation of sister chromatid separation (24–26), and Kinesin-7/CENP-E, a component of
the kinetochore (27). MAD2/MAD2L1 and Kinesin- 7/CENP-E were validated as being
essential in MCF-10A (table S3 and Fig. 2B). CENP-E depletion also inhibited growth in
MDA-MB-435 (table S3 and Fig. 2C). Considered together, these studies showed that
multiplex RNAi screens successfully identified essential components of cell growth and
survival networks.
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We also screened higher complexity populations containing 10,000 (10K) or 20,000 (20K)
shRNAs. The 10K pool was introduced into MDA-MB-231, T-47D and ZR-75-1. The most
complex pool (20K) was introduced into MCF-10A to allow direct comparison with the 6K
screen. In all cases, cell numbers were scaled to maintain a representation of 1000 cells per
shRNA. The quality of each screen was similar, with high correlations between biological
replicates (table S4). We assessed the consistency of the MCF-10A screens by comparing
depleted gene sets for the 6K and 20K pools. FDR thresholds were the same for both data sets
(q < 0.1), but the fold-change criterion was relaxed from 2-fold to 1.5-fold for the 20K screen
so that similar numbers of candidates were compared. A set of 172 genes (P = 1.123 × 10−9)
overlapped in both data sets, despite some differences in the protocols used to carry out each
screen, and most of the validated targets from the 6K screen were found in the overlapping list
of essential genes (tables S5 and S6). This suggests that a pool of ~20K shRNAs can be
effectively screened.
We next sought to uncover cell line–specific genetic sensitivities that might reflect differences
in the genetic constitutions of MCF-10A, MDA-MB-231, MDA-MB-435, and ZR-75.1. Initial
comparisons focused on the 6K screens done with MCF-10A and MDA-MB-435. Filtering for
shRNAs that had a low FDR (q < 0.1) and at least 2-fold depletion in MCF-10A but no more
than 1.2-fold depletion in MDA-MB-435 yielded 35 genes (table S7). This compares to 166
genes that were important for growth in both cell lines and 3 genes that were differentially
required in MDA-MB-435 (Fig. 2D and table S7). Among the candidates required in MCF-10A
were two components of P-TEFb, CDK9 and cyclin T2 (28). We verified this differential
sensitivity using both conditional shRNA expression (Fig. 2, B and C) and pharmacological
inhibition (Fig. 2D). CDK9 is a DRB-sensitive kinase (28). Although DRB may also target
other proteins, MCF-10A showed greater sensitivity to its effects than MDA-MB-435 cells
(Fig. 2D).
We repeated the 6K screens of MCF-10A and MDA-MB-435 cells on the same array platform
as the 10K screens of MDA-MB-231, T-47D, and ZR-75.1 cells and integrated the results (table
S8). This was possible because more than 90% of the 6K shRNA set was contained within the
10K pool. Clustering of the resulting sensitivities (i.e., by fold-change, considering only
shRNAs with q < 0.1) yielded a dendrogram wherein the more normal MCF-10A segregated
from the other, more transformed lines (Fig. 3A). MDA-MB-435 also segregated, perhaps
reflecting the observation that it is more related, by expression profiling, to melanoma than
breast epithelia. Finally, the remaining lines separated into a group containing T-47D and
ZR-75.1, both luminal tumor cell lines, and MDA-MB-231, a basal tumor cell line (29) (Fig.
3A).
Viewing this portrait of shRNA sensitivity in more detail revealed a number of pathways and
complexes that were differentially required in MCF-10A. These included epidermal growth
factor receptor (EGFR), an effect that could be reproduced pharmacologically using the EGFR
inhibitor Tarceva (30) (Fig. 3B). DNA methyltransferases also scored either above or close to
the threshold (table S8 and Fig. 3B). In accord with these results, MCF-10A cells showed a
more than 50-fold greater sensitivity to 5-aza-deoxycytidine, a methyltransferase suicide
substrate (31), than the other cell lines. As a final example, numerous proteasome subunits
were preferentially depleted from MCF-10A (table S8 and Fig. 3B). These cells showed the
greatest sensitivity to a proteasome inhibitor, MG-132 (32). Interestingly, MDA-MB-435
showed an intermediate level of sensitivity to the drug, and this was reflected precisely in their
intermediate level of depletion of proteasomal shRNAs during the screen (table S8 and Fig.
3B).
We have validated a highly scalable approach for screening shRNA libraries. Although we
used a phenotypic filter reflecting growth and survival, virtually any characteristic that allows
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separation of phenotypically distinct cells can be applied. We also validated the ability of
functional shRNA screening to separate cell lines based on their genetic vulnerabilities in a
manner that reflects their already defined characteristics (e.g., immortal versus tumor, basal
versus luminal). Although one could attribute selective dependency to culture conditions in
some cases, the overwhelming concordance of the shRNAs that affect proliferation and
survival across these lines, many of which are cultured identically, strongly argues against this
being a pervasive explanation. In all, this approach enables genomewide screens for tumor-
specific vulnerabilities to be carried out on large numbers of tumor lines. Moreover, it permits
rational searches for lesions that synergize with existing therapeutics to produce a path toward
genetically informed combination therapies.
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Fig. 1.
Experimental approach. (A) shRNA plasmids were packaged into retroviruses in triplicate and
introduced into replicate target cell populations at a multiplicity of ~0.3 to achieve ~1 integrant
per cell. Over a 2- week culture period, time points were collected on day 2 or day 4 after
infection and then once each week for 2 weeks. (B) The shRNA guide strand and the barcode
region were amplified from genomic DNA from screening pools. Polymerase chain reaction
(PCR) products were gel-purified, labeled, and hybridized to multiplex arrays in competition
with a common reference.
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Fig. 2.
Validation of genes essential to multiple cell lines. Cell viability assays (bars) were performed
on cell lines (MCF-10A or MDA-MB- 435) expressing individual candidate shRNAs. Tables
below the graphs show the level of target suppression, determined by quantitative real-time
fluorescence PCR, with or without shRNA induction (indicated). An shRNA targeting
luciferase (FF) and no shRNA serve as negative controls. (A) APC subunits ANAPC2 and
ANAPC4 were suppressed by multiple hairpins in MCF-10A (1 to 5 for ANAPC4 and 1 to 4
for ANAPC2). Cell viability assays were carried out for 7 days after shRNA induction. (B)
Nineteen additional inducible MCF- 10A cell lines were generated to validate shRNAs that
were depleted in the screen. Viability assays were carried out for 11 days. (C) Validation of
shRNAs that were depleted (left of the yellow line) or not depleted (right of the yellow line)
in MDA-MB-435 cells. Viability assays were carried out for 11 days. (D) The Venn diagram
illustrates the 166 depleted genes that were common to both screens and the 35 and 3 genes
specifically depleted from MCF-10A and MDA-MB-435, respectively. shRNAs targeting P-
TEFb components CDK9 and cyclin T2 were both depleted specifically in MCF-10A. The
graph shows a dose-response curve for growth inhibition of MCF-10A and MDA-MB-435
cells by DRB over a 72-hour period.
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Fig. 3.
Cross-comparison of straight lethal screens in five different cell lines. (A) A heat map and
dendrogram were generated by clustering based on shRNAs that showed depletion in at least
one cell line. (B) shRNAs targeting selected complexes or pathways were chosen from (A) to
highlight responses to EGFR, methyltransferase, and proteasome lesions. Pharmacological
inhibition of these pathways by treatment with Tarceva (C), 5-aza-deoxycytidine (D), or
MG-132 (E) was used to validate the predictions of the shRNA screen.
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